Short answer
Protara Therapeutics, Inc. (TARA) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$13M
- −18.2% YoY · +11.4% QoQ
- EPS (diluted)
- −$0.31
- +35.4% YoY · +13.9% QoQ
Source: XBRL data from the Protara Therapeutics, Inc. (TARA) Q3 2025 10-Q on SEC EDGAR. USD.
Protara Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no approved products or product-sales revenue
- Net loss $13.3M vs $11.2M YoY; operating loss $14.8M vs $12.3M
- IV Choline Chloride R&D $1.8M vs $0.8M; largest product-candidate increase
- Cash, equivalents and marketable debt securities $133.6M vs $170.3M at December 31, 2024
- Operating cash use $39.4M for nine months; additional capital needed despite funding through at least twelve months
Risk Factors
- No risk-factors section provided; filing text begins with Item 2 and contains no disclosed quarterly risk changes
- Regulatory and compliance disclosures limited to required certifications and Rule 10b5-1 trading-arrangement reporting
- Financial risk indicators include marketable U.S. Treasury securities and corporate bonds as of September 30, 2025
- Capital-raising exposure reflected in April 2024 and December 2024 offerings, prefunded warrants, and common warrants
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Protara Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.